NCT04008797 2026-02-27
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
Clinical Trials
10 trialsNCT07282184 2025-12-18
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
Tongji Hospital
Phase 1/2 Recruiting
NCT05091346 2025-10-24
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT03781934 2025-07-01
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Medivir
Phase 1/2 Completed
NCT05620134 2024-10-15
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
Phase 1/2 Active not recruiting
NCT04444167 2024-04-25
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
Akeso
Phase 1/2 Completed
NCT05842317 2024-02-09
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT03867370 2023-11-29
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Terminated
NCT04911959 2023-02-06
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1/2 Unknown
NCT00946153 2019-02-01
Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
Eisai Inc.
Phase 1/2 Completed